Addex Therapeutics (ADDXF) Stock Price, News & Analysis

Company Overview

Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing orally available small-molecule therapies that target G protein-coupled receptors (GPCRs). The company’s approach emphasizes allosteric modulation, which is designed to influence receptor activity at sites distinct from where the body’s natural signaling molecules bind.

Addex’s development programs have focused primarily on neurological and central nervous system disorders. Its lead investigational product, dipraglurant, is an mGlu5 negative allosteric modulator being developed for conditions including levodopa-induced dyskinesia in people with Parkinson’s disease. The company has also advanced ADX71149, an mGlu2 positive allosteric modulator investigated for neurological disorders, including epilepsy-related indications.

Founded in 2002 and headquartered in Geneva, Switzerland, Addex has pursued research and development through internal programs and collaborations with pharmaceutical companies and academic institutions. Its shares trade on the SIX Swiss Exchange under the symbol ADXN and in the United States on the over-the-counter market under the symbol ADDXF.

Key Stats

• Today's Range: $0.99 to $0.99
• 50-Day Range: $0.99 to $0.99
• 52-Week Range: $0.99 to $0.99
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ADDXF
• CIK: N/A
• Web: www.addextherapeutics.com
• Phone: 41 22 884 1555
• Fax: N/A
• Employees: 26
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.25